P55.9

Hemolytic disease of newborn, unspecified

Billable FY2026 2025-10-01 → 2026-09-30

This is the unspecified option. 3 more specific codes sit alongside it. Worth checking whether the documentation supports one of them.

Exclusions 10 never code together

Excludes1

congenital stenosis and stricture of bile ducts (Q44.3)Q44.3
Crigler-Najjar syndrome (E80.5)E80.5
Dubin-Johnson syndrome (E80.6)E80.6
Gilbert syndrome (E80.4)E80.4
hereditary hemolytic anemias (D55-D58)D55-D58

Excludes2

congenital malformations, deformations and chromosomal abnormalities (Q00-Q99)Q00-Q99
endocrine, nutritional and metabolic diseases (E00-E88)E00-E88
injury, poisoning and certain other consequences of external causes (S00-T88)S00-T88
neoplasms (C00-D49)C00-D49
tetanus neonatorum (A33)A33

Excludes1 — never code together. The excluded condition and this one are mutually exclusive.

Excludes2 — not included here, but the patient may have both. Code both when documented.

Instructional notes 2

Notes

Codes from this chapter are for use on newborn records only, never on maternal records

Includes

conditions that have their origin in the fetal or perinatal period (before birth through the first 28 days after birth) even if morbidity occurs later

Index entries leading here 5

Anemia (essential) (general) (hemoglobin deficiency) (infantile) (primary) (profound) D64.9
- congenital P61.4
  - due to isoimmunization NOS P55.9
- erythroblastic
  - newborn P55.9
Disease, diseased — see also Syndrome
- hemolytic (newborn) P55.9
Jaundice (yellow) R17
- newborn P59.9
  - due to or associated with
    - isoimmunization NOS P55.9
    - hemolytic disease P55.9
    - incompatibility, maternal/fetal NOS P55.9
Erythroblastosis (fetalis) (newborn) P55.9
Isoimmunization NEC — see also Incompatibility
- newborn P55.9

Alongside this code 3 same parent — P55

Additional references

AHA Coding Clinic® Licence required

Official coding advice for this code. Published by the American Hospital Association. Not included in this installation.

Present FY2024–FY2027.